参考文献/References:
[1] Sarchielli P.Medication-overuse headache:an update[J].J Headache Pain,2015,16(Suppl 1):A46.
[2] Giamberardino MA, Mitsikostas DD. Update on medication-overuse headache and its treatment[J].Curr Treat Options Neurol,2015,17(8):368.
[3] Westergaard ML,Hansen EH,Glümer C,et al.Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review[J].Cephalalgia,2014,34(6):409-425.
[4] Shahbeigi S,Fereshtehnejad SM,Mohammadi N,et al.Epidemiology of headaches in Tehran urban area: a population-based cross-sectional study in district 8, year 2010[J].Neurol Sci,2013,34(7):1157-1166.
[5] Stark RJ,Ravishankar K,Siow HC,et al.Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review[J].Cephalalgia,2013,33(4):266-283.
[6] Peters GA,Horton BT.Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects[J].Proc Staff Meet Mayo Clin,1951,26(9):153-161.
[7] Horton BT,Peters GA.Clinical manifestations of excessive use of ergotamine preparations and mangement of withdrawal effect: report of 52 cases[J].Headache,1963,2:214-227.
[8] Evers S,Marziniak MF,pathophysiology.And treatment of medication-overuse headache[J].Lancet Neurol,2010,9(4):391-401.
[9] Diener HC, Wilkinson M.Drug Induced Headache [M]. Springer,1988):1-175.
[10] Headache Classification Committee of the International Headache Society.Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society[J].Cephalalgia,1988,8(Suppl 7):1-96.
[11] Headache Classification Committee of the International Headache Society.ICHD-II.the international classification of headache disorders:2nd edition[J].Cephalalgia,2004,24(suppl 1):9-160.
[12] Headache Classification Committee,Olesen J,Bousser MG,et al.New appendix criteria open for a broader concept of chronic migraine[J].Cephalalgia,2006,26(6):742-746.
[13] Headache Classification Committee of the International Headache Society(IHS).The international classification of headache disorders, 3rd edition(beta version)[J].Cephalalgia,2013,33(9):629-808.
[14] Hagen K,Linde M,Steiner TJ,et al.Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trøndelag Health Studies[J].Pain,2012,153(1):56-61.
[15] Jonsson P,Hedenrud T,Linde M.Epidemiology of medication overuse headache in the general Swedish population[J].Cephalalgia,2011,31(9):1015-1022.
[16] Straube A,Pfaffenrath V,Ladwig KH,et al.Prevalence of chronic migraine and medication overuse headache in Germany--the German DMKG headache study[J].Cephalalgia,2010,30(2):207-213.
[17] Jay GW,Barkin RL.Primary headache disorders- part 2: tension-type headache and medication overuse headache[J].Dis Mon,2017,63(12):342-367.
[18] Da Silva A.N.,lake a.E.3rd.clinical aspects of medication overuse headaches[J].Headache,2014,54(1):211-217.
[19] Limmroth V,Katsarava Z,Fritsche G,et al.Features of medication overuse headache following overuse of different acute headache drugs[J].Neurology,2002,59(7):1011-1014.
[20] Tepper SJ.Medication-overuse headache[J].Continuum(Minneap Minn),2012,18(4):807-822.
[21] Sarchielli P,Corbelli I,Messina P,et al.Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study[J].European Journal of Neurology,2016,23(1):85-91.
[22] Wiendels NJ,Knuistingh Neven A,Rosendaal FR,et al.Chronic frequent headache in the general population: prevalence and associated factors[J].Cephalalgia,2006,26(12):1434-1442.
[23] Westergaard ML,Glümer C,Hansen EH,et al.Medication overuse, healthy lifestyle behaviour and stress in chronic headache: Results from a population-based representative survey[J].Cephalalgia,2016,36(1):15-28.
[24] Ferrari A,Leone S,Vergoni AV,et al.Similarities and differences between chronic migraine and episodic migraine[J].Headache,2007,47(1):65-72.
[25] Cevoli S,Sancisi E,Grimaldi D,et al.Family history for chronic headache and drug overuse as a risk factor for headache chronification[J].Headache,2009,49(3):412-418.
[26] Di Lorenzo C,Coppola G,Currà A,et al.Cortical response to somatosensory stimulation in medication overuse headache patients is influenced by angiotensin converting enzyme(ACE)I/D genetic polymorphism[J].Cephalalgia,2012,32(16):1189-1197.
[27] Bath KG,Lee FS.Variant BDNF(Val66Met)impact on brain structure and function[J].Cogn Affect Behav Neurosci,2006,6(1):79-85.
[28] Di Lorenzo C,Di Lorenzo G,Sances G,et al.Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism[J].J Headache Pain,2009,10(5):349-355.
[29] Cargnin S,Viana M,Ghiotto N,et al.Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy[J].European Journal of Neurology,2014,21(7):989-995.
[30] Cevoli S,Mochi M,Scapoli C,et al.A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse[J].European Journal of Neurology,2006,13(9):1009-1013.
[31] Srikiatkhachorn A,Anthony M.Platelet serotonin in patients with analgesic-induced headache[J].Cephalalgia,1996,16(6):423-426.
[32] Hering R,Glover V,Pattichis K,et al.5HT in migraine patients with medication-induced headache[J].Cephalalgia,1993,13(6):410-412.
[33] Srikiatkhachorn A,Le Grand SM,Supornsilpchai W,et al.Pathophysiology of medication overuse headache--an update[J].Headache,2014,54(1):204-210.
[34] Ayzenberg I,Obermann M,Oberman M,et al.Increased activity of serotonin uptake in platelets in medication overuse headache following regular intake of analgesics and triptans[J].J Headache Pain,2008,9(2):109-112.
[35] Supornsilpchai W,Le Grand SM,Srikiatkhachorn A.Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache[J].Headache,2010,50(2):185-197.
[36] Srikiatkhachorn A,Tarasub N,Govitrapong P.Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache[J].Headache,2000,40(5):343-350.
[37] Dobson,F C,Tohyama Y,et al.Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain[J].Cephalalgia,2004,24(1):2-11.
[38] Reuter U,Salomone S,Ickenstein GW,et al.Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats[J].Cephalalgia,2004,24(5):398-407.
[39] Rossi C,Pini LA,Cupini ML,et al.Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels[J].Eur J Clin Pharmacol,2008,64(1):1-8.
[40] Akerman S,Holland PR,Goadsby PJ.Cannabinoid(CB1)receptor activation inhibits trigeminovascular neurons[J].J Pharmacol Exp Ther,2007,320(1):64-71.
[41] Sarchielli P,Rainero I,Coppola F,et al.Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid[J].Cephalalgia,2008,28(7):714-722.
[42] Vieira DS,Naffah-Mazzacoratti Mda G,Zukerman E,et al.Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine[J].Headache,2007,47(6):842-847.
[43] Rainero I,Ferrero M,Rubino E,et al.Endocrine function is altered in chronic migraine patients with medication-overuse[J].Headache,2006,46(4):597-603.
[44] Perrotta A,Arce-Leal N,Tassorelli C,et al.Acute reduction of anandamide-hydrolase(FAAH)activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment[J].Headache,2012,52(9):1350-1361.
[45] Ayzenberg I,Obermann M,Nyhuis P,et al.Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures[J].Cephalalgia,2006,26(9):1106-1114.
[46] Coppola G,Currà A,Di Lorenzo C,et al.Abnormal cortical responses to somatosensory stimulation in medication-overuse headache[J].BMC Neurol,2010,10:126.
[47] Perrotta A,Serrao M,Sandrini G,et al.Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control[J].Cephalalgia,2010,30(3):272-284.
[48] Zappaterra M,Guerzoni S,Cainazzo MM,et al.Basal cutaneous pain threshold in headache patients[J].J Headache Pain,2011,12(3):303-310.
[49] Ferraro D,Vollono C,Miliucci R,et al.Habituation to pain in "medication overuse headache": a CO2 laser-evoked potential study[J].Headache,2012,52(5):792-807.
[50] De Felice M,Porreca F.Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache[J].Cephalalgia,2009,29(12):1277-1284.
[51] Okada-Ogawa A,Porreca F,Meng ID.Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal Horn neurons[J].J Neurosci,2009,29(50):15828-15835.
[52] De Felice M,Ossipov MH,Wang R,et al.Triptan-induced latent sensitization: a possible basis for medication overuse headache[J].Ann Neurol,2010,67(3):325-337.
[53] Supornsilpchai W,Le Grand S.M.,srikiatkhachorn a.cortical hyperexcitability and mechanism of medication-overuse headache[J].Cephalalgia,2010,30(9):1101-1109.
[54] Latremoliere A,Woolf CJ.Central sensitization: a generator of pain hypersensitivity by central neural plasticity[J].J Pain,2009,10(9):895-926.
[55] Riederer F,Marti M,Luechinger R,et al.Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety[J].World J Biol Psychiatry,2012,13(7):517-525.
[56] Riederer F,Gantenbein AR,Marti M,et al.Decrease of gray matter volume in the midbrain is associated with treatment response in medication-overuse headache: possible influence of orbitofrontal cortex[J].J Neurosci,2013,33(39):15343-15349.
[57] Lai TH,Chou KH,Fuh JL,et al.Gray matter changes related to medication overuse in patients with chronic migraine[J].Cephalalgia,2016,36(14):1324-1333.
[58] Grazzi L,Chiapparini L,Ferraro S,et al.Chronic migraine with medication overuse pre-post withdrawal of symptomatic medication: clinical results and FMRI correlations[J].Headache,2010,50(6):998-1004.
[59] Ferraro S,Grazzi L,Mandelli ML,et al.Pain processing in medication overuse headache: a functional magnetic resonance imaging(fMRI)study[J].Pain Med,2012,13(2):255-262.
[60] Fumal A,Laureys S,Di Clemente L,et al.Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine[J].Brain,2006,129(Pt 2):543-550.
[61] Johnson JL,Hutchinson MR,Williams DB,et al.Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment[J].Cephalalgia,2013,33(1):52-64.
[62] Saper JR,Hamel RL,Lake AE.Medication overuse headache(MOH)is a biobehavioural disorder[J].Cephalalgia,2005,25(7):545-546.
[63] Jonsson P,Jakobsson A,Hensing G,et al.Holding on to the indispensable medication--a grounded theory on medication use from the perspective of persons with medication overuse headache[J].J Headache Pain,2013,14(1):43.
[64] Munksgaard SB,Jensen RH.Medication overuse headache[J].Headache,2014,54(7):1251-1257.
[65] Rossi P,Faroni JV,Nappi G.Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache[J].European Journal of Neurology,2011,18(3):396-401.
[66] Rossi P,Di Lorenzo C,Faroni J,et al.Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs[J].Cephalalgia,2006,26(9):1097-1105.
[67] Rossi P,Faroni JV,Tassorelli C,et al.Advice alone versus structured detoxification programmes for complicated medication overuse headache(MOH): a prospective, randomized, open-label trial[J].J Headache Pain,2013,14(1):10.
[68] Grande RB,Aaseth K,Benth J,et al.Reduction in medication-overuse headache after short information. The Akershus study of chronic headache[J].European Journal of Neurology,2011,18(1):129-137.
[69] Evers,S,Jensen,et al.European federation of neurological,S.treatment of medication overuse headache-guideline of the EFNS headache panel[J].Eur J Neurol,2011,18(9):1115-1121.
[70] Bigal ME,Rapoport AM,Sheftell FD,et al.Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes[J].Cephalalgia,2004,24(6):483-490.
[71] Katsarava Z,Obermann M.Medication-overuse headache[J].Curr Opin Neurol,2013,26(3):276-281.
[72] Saper JR,Da Silva AN.Medication overuse headache: history, features, prevention and management strategies[J].CNS Drugs,2013,27(11):867-877.
[73] Pascual J,Berciano J.Daily chronic headache in patients with migraine induced by abuse of ergotamine-analgesics: response due to a protocol of outpatient treatment[J].Neurologia,1993,8(7):212-215.
[74] Tassorelli C,Jensen R,Allena M,et al.A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study[J].Cephalalgia,2014,34(9):645-655.
[75] Hollanda L,Monteiro L,Melo A.Botulinum toxin type a for cephalic cutaneous allodynia in chronic migraine: a randomized, double-blinded, placebo-controlled trial[J].Neurol Int,2014,6(4):5133.
[76] Estemalik E,Tepper S.Preventive treatment in migraine and the new US guidelines[J].Neuropsychiatr Dis Treat,2013,9:709-720.
[77] Diener HC,Holle D,Solbach K,et al.Medication-overuse headache: risk factors, pathophysiology and management[J].Nat Rev Neurol,2016,12(10):575-583.
[78] White HS.Molecular pharmacology of topiramate: managing seizures and preventing migraine[J].Headache,2005,45(Suppl 1):S48-S56.
[79] Roceanu A,Antochi F,Bajenaru O.Chronic migraine - new treatment options[J].Maedica(Buchar),2014,9(4):401-404.
[80] Diener HC,Bussone G,Van Oene JC,et al.Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study[J].Cephalalgia,2007,27(7):814-823.
[81] Silberstein SD,Lipton RB,Dodick DW,et al.Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial[J].Headache,2007,47(2):170-180.
[82] Silberstein S,Lipton R,Dodick D,et al.Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of Life and other efficacy measures[J].Headache,2009,49(8):1153-1162.
[83] Silberstein SD,Blumenfeld AM,Cady RK,et al.OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline[J].J Neurol Sci,2013,331(1/2):48-56.
[84] Martelletti P,Katsarava Z,Lampl C,et al.Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation[J].J Headache Pain,2014,15(1):47.